FPA-150 is under clinical development by Amgen and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect FPA-150’s likelihood of approval (LoA) and phase transition for Endometrial Cancer took place on 12 Jan 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
In addition, the same event on 12 Jan 2022 decreased FPA-150’s LoA and PTSR for Metastatic Breast Cancer, and decreased LoA and PTSR for Triple-Negative Breast Cancer (TNBC).
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their FPA-150 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
FPA-150 is under development for the treatment of advanced or metastatic breast, triple negative breast cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer and endometrial cancer. The drug candidate is a monoclonal antibody acts by targeting B7-H4.
It was also under development for the treatment of bladder cancer.
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in six focused disease areas including cardiovascular diseases, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television and online media. Amgen is headquartered in Thousand Oaks, California, the US.
Quick View FPA-150 LOA Data
|Highest Development Stage|